Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

8.080 -0.190 (-2.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 Next >
US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert
U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in premarket. 
Via Benzinga
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
Aurinia Pharmaceuticals (AUPH) meets Louis Navellier’s growth criteria with strong earnings surprises, accelerating revenue, and improving margins. A solid pick for growth-focused investors. 
Via Chartmill
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance
Aurinia posts Q1 profit and 25% LUPKYNIS sales growth, reports $62.47 million revenue, and reaffirms full-year guidance. 
Via Benzinga
Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens
The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million. 
Via Stocktwits
Earnings Scheduled For May 12, 2025
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Earnings Outlook For Aurinia Pharmaceuticals
Via Benzinga
Why Aurinia Pharmaceuticals Stock Is Slumping Today
The biotech's premium valuation doesn't seem to be sitting well with investors. 
Via The Motley Fool
Uncovering Potential: Aurinia Pharmaceuticals's Earnings Preview
Via Benzinga
Is AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) following the Minervini trend for explosive growth?
Should you consider AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) for high growth investing? A fundamental and technical analysis of (NASDAQ:AUPH). 
Via Chartmill
Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet
Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%. 
Via Stocktwits
Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations
Aurinia Pharmaceuticals reported Q4 earnings of 1 cent per share, beating estimates, with LUPKYNIS sales up 36%. 
Via Benzinga
AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
AUPH stock results show that Aurinia Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Aurinia Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Aurinia Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings. 
Via Benzinga
Aurinia Pharmaceuticals Finds No Buyer After Strategic Business Review, Launches Stock Buyback
Aurinia Pharmaceuticals Q4 2023 results: EPS loss $(0.19), sales $45.1 million. AUR200 development halted. Strategic review concludes. $150 million share buyback initiated. 
Via Benzinga
What's Going On With Aurinia Pharmaceuticals Stock?
Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) shares are trending on social media Friday. The company provided its preliminary, unaudited fourth-quarter and fiscal year 2023 financial results. What To... 
Via Benzinga
What's Going On With Aurinia Pharmaceuticals Stock?
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher, adding to gains of more than 17% over the last week. 
Via Benzinga
This Oil Giant Is 'Not Great, Not Bad,' But Jim Cramer Says 'I'm Sticking With My Coterra'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BP (NYSE: BP) is "not great, not bad." He added, "This whole group is going through a real re-evaluation. 
Via Benzinga
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday
The biotech's board is exploring strategic alternatives to boost shareholder value. 
Via The Motley Fool
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top... 
Via Benzinga
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout
The company makes a lupus nephritis treatment that could easily bolt onto a suitor, analysts say. 
Via Investor's Business Daily
Why Are Aurinia Pharmaceuticals Shares Trading Higher Today
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) initiated an exploration of strategic alternatives, including a potential sale, merger, or  
Via Benzinga
Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket
Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's the final day of trading this week and we're starting off with a breakdown of the biggest pre-market stock movers worth watching today! 
Via InvestorPlace
Tesla, Nike, Sigilon Therapeutics Among Top Trending Stocks Today
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS